The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned ...
N4 Pharma Plc (AIM: N4P), the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses ...
The company is developing treatments to rebalance, rather than suppress, immune function in people with inflammatory ...
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a ...